Omeros Corporation's stock rebounded after successful data analysis for narsoplimab, showing 68% lower death risk in HSCT-TMA patients compared to historical controls. FDA requested new statistical analysis for narsoplimab's BLA resubmission, which proved successful, leading to a potential approval by late 2025. Financial risks include limited cash runway and potential market constraints due to upcoming generic competition and insurance issues.
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that an independent statistical group has completed the primary statistical analysis agreed with the FDA for narsoplimab, Omeros' first-in-class monoclonal antibody inhibiting the lectin pathway of complement, in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a life-threatening complication in both adult and pediatric hematopoietic stem cell transplantation (HSCT). Th.
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that two abstracts directed to zaltenibart (OMS906), Omeros' investigational inhibitor of MASP-3, the key activator of the alternative pathway of complement, will be presented at the 66th Annual Meeting of the American Society of Hematology (ASH), to be held December 7-10, 2024 in San Diego. The zaltenibart abstracts are directed to the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare, life-threatening hem.
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced an update on its progress toward planned resubmission of its biologics license application (“BLA”) for narsoplimab, the company's first-in-class antibody targeting MASP-2, the effector enzyme of the lectin pathway of complement, in hematopoietic stem cell transplant-associated thrombotic microangiopathy (“TA-TMA”). In last week's quarterly earnings release and associated call, Omeros stated that it was awaiting feedback.
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2024, on Wednesday, November 13, 2024, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the.
Omeros Corporation (NASDAQ:OMER ) Q2 2024 Results Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Jennifer Cook Williams - Investor Relations, Cook Williams Communications, Inc. Gregory Demopulos - Chairman and Chief Executive Officer David Borges - Chief Accounting Officer Catherine Melfi - Chief Regulatory Officer Nadia Dac - Chief Commercial Officer Andreas Grauer - Chief Medical Officer Steven Whitaker - Vice President-Clinical Development Conference Call Participants Steve Brozak - WBB Securities Olivia Brayer - Cantor Fitzgerald John Gionco - Needham & Company Operator Good afternoon and welcome to today's earnings call for Omeros Corporation. At this time, all participants are in a listen-only mode.
Omeros Corporation's Q1 2024 Earnings Conference Call will begin at 4:30 PM ET on May 15, 2024. The call will feature company representatives including Jennifer Williams, Greg Demopulos, Mike Jacobsen, Andreas Grauer, Steve Whitaker, Nadia Dac, and Catherine Melfi. Participants on the call include Steve Brozak and Olivia Brayer from WBB Securities and Cantor Fitzgerald, respectively. All participants are currently in listen-only mode.
Omeros Corporation (OMER) Q4 2023 Earnings Call Transcript
Omeros Corporation focuses on small-molecule and antibody drugs for common disorders and rare diseases. The company has prioritized the resubmission of its BLA for Narsoplimab for TA-TMA treatment and is advancing Phase-3 clinical trials for MASP-3 inhibitor OMS906. Narsoplimab holds promise for treating TA-TMA, COVID-19, and Lupus Nephritis but faces competition in the latter two conditions.
Omeros Corp said on Monday it will discontinue a trial studying its therapy to treat a type of kidney disease after it failed to meet the main goal of the late-stage study.